Zocilurtatug pelitecan shows promising results as a DLL3-targeted therapy for small cell lung cancer, with high response rates and ongoing trials.

IceCure Medical Ltd. (NASDAQ: ICCM) ("IceCure", "IceCure Medical" or the "Company"), developer of minimally-invasive cryoablation technology that destroys tumors by freezing as an option to surgical ...

Adding immunotherapy to chemotherapy before surgery for patients with operable non-small cell lung cancer—the leading cause of cancer deaths worldwide—improved long-term survival overall compared with ...

Roche said Tecentriq combined with lurbinectedin shows significant survival benefits for patients with extensive-stage small cell lung cancer. The Swiss pharmaceutical company said Tuesday that ...

The observation that mRNA vaccines can sensitize tumors to immunotherapy has researchers eager to test how mRNA’s ability to activate the immune system could be harnessed in oncology.

A new study finds that combining the COVID vaccine with immunotherapy may nearly double cancer survival rates — patients ...

The use of immunotherapy in patients with various types of cancer has led to dramatic increases in survival. Increased median ...

Sacituzumab tirumotecan significantly reduced progression or death risk by 51% compared to chemotherapy in EGFR-mutated non-small cell lung cancer resistant to EGFR tyrosine kinase inhibitors. The ...

In recent research, treatment with osimertinib plus a platinum–pemetrexed chemotherapy combination resulted in statistically significant and clinically meaningful improvement in overall survival in ...

In the current study, the association between mRNA COVID vaccination and survival was strongest among patients whose tumors ...

Comparable overall survival seen at seven and 10 years, lung cancer-specific survival, and recurrence-free survival.

Understanding the patterns of acquired resistance to epidermal growth factor receptor (EGFR) TKI treatment has led to more effective combination therapy and continues to drive development of novel ...